SCHEMBL23714784

SCHEMBL23714784

COc1cc(-c2cccc(-c3csc(NC(=O)CNC(=O)c4cccc(S(=O)(=O)C(C)C)c4)n3)c2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 7/20 0.53
▸ KDM4A O75164 2/20 0.47
▸ KDM4B O94953 2/20 0.47
▸ KDM5B Q9UGL1 2/20 0.47
▸ KDM5C P41229 1/20 0.46
▸ MAPT P10636 5/20 0.44
▸ ALDH1A1 P00352 6/20 0.43
▸ THRB P10828 1/20 0.43
▸ ROCK1 Q13464 5/20 0.43
▸ HPGD P15428 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PRKACA P17612 1/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ LMNA P02545 2/20 0.42
▸ USP2 O75604 2/20 0.41
▸ PHGDH O43175 1/20 0.41
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23714993 0.89 CYP3A4 (0.49) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL30058886 0.89 MAPT (0.47) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL23705010 0.89 MAPT (0.47) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL23704855 0.89 ALDH1A1 (0.47) KDM4AKDM4BKDM5BKDM5CMAPT
SCHEMBL30061168 0.89 ALDH1A1 (0.47) KDM4AKDM4BKDM5BKDM5CMAPT
SCHEMBL25499055 0.89 MAPT (0.43) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL25180078 0.88 KDM4A (0.46) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL25499070 0.88 KDM4A (0.45) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL25202913 0.88 KDM4A (0.45) CYP3A4KDM4AKDM4BKDM5BKDM5C
SCHEMBL23704835 0.88 KDM4A (0.46) CYP3A4KDM4AKDM4BKDM5BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 — — CN disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CYP3A4 3718/4885KDM4A 2166/4885KDM4B 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback